Document Detail

Comparative Effect of Telmisartan vs Lisinopril on Blood Pressure in Patients of Metabolic Syndrome.
MedLine Citation:
PMID:  25440999     Owner:  NLM     Status:  Publisher    
Objective: The present study was planned to study comparative effects of telmisartan vs lisinopril on blood pressure in patients of metabolic syndrome Methods: The study was carried out on 62 patients of metabolic syndrome from Dec 2010 to Oct 2012 in OPD of Institute. There were two groups, A and B. Group A- Telmisartan (31 patients) and Group B- Lisinopril (31 patients) receiving Telmisartan 40 mg and lisinopril 5 mg orally once a day respectively for 12 weeks. The diagnosis of essential hypertension was made by the physician based on two measurement of blood pressure on two different occasions using auscultatory method and was done at initial stage and repeated after 6 weeks and 12 weeks of treatment in Group A and Group B patients. Key findings: Our study found that telmisartan or lisinopril treatment for 12 weeks leads to statistically significant (p<0.001) reduction in both SBP and DBP at 6 and 12 weeks when compared with baseline, whereas comparison between telmisartan and lisinopril treatment failed to show any statistically significant effect. Conclusion: Treatment of metabolic patients with telmisartan or lisinopril for management of hypertension reduced both Systolic blood pressure (SBP) as well as Diastolic blood pressure (DBP) statistically significantly during 12 weeks treatment. However, telmisartan and lisinopril treatment found effective.
Pradip N Gore; Vandana A Badar; Mrunalini M Hardas; Varsha J Bansode
Related Documents :
25277169 - Intensity-dependent reductions in resting blood pressure following short-term isometric...
11948289 - The hypertrophic heart rat: a new normotensive model of genetic cardiac and cardiomyocy...
8319999 - Circadian blood pressure variation in transgenic hypertensive rats.
9109619 - Food restriction reduces sympathetic support of blood pressure in spontaneously hyperte...
9403559 - Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats.
9922389 - Two blood pressure/cardiac mass quantitative trait loci on chromosome 3 in dahl rats.
12377619 - Successful resuscitation by emergency room thoracotomy in a patient in agonal state wit...
12018559 - Status of lifestyle modifications in hypertension.
24698199 - Acute hemodynamic response and uremic toxin removal in conventional and extended hemodi...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-28
Journal Detail:
Title:  Endocrine, metabolic & immune disorders drug targets     Volume:  -     ISSN:  2212-3873     ISO Abbreviation:  Endocr Metab Immune Disord Drug Targets     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  101269157     Medline TA:  Endocr Metab Immune Disord Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antibacterial activity and genotypic-phenotypic characteristics of bacteriocin-producing Bacillus su...
Next Document:  Mitral valve repair in asymptomatic patients with severe mitral regurgitation: pushing past the tipp...